Table 5.

Comparison of adverse events of severe intensity between control and Cerebrolysin groups

	Control (N = 328)	Cerebrolysin (N = 134)	p value
Pneumonia	29 (8.84%)	12 (8.96%)	1.000
Urinary tract infection	18 (5.49%)	8 (5.97%)	0.986
CSF infection	3 (0.91%)	2 (1.49%)	0.630
Acute renal failure	17 (5.18%)	4 (2.99%)	0.434
Pulmonary embolism	5 (1.52%)	1 (0.75%)	0.678
Acute cholecystitis	0 (0.00%)	1 (0.75%)
Myocardial infarction	14 (4.29%)	5 (3.73%)	1.000
Severe adverse event	82 (25.0%)	31 (23.1%)	0.761

CSF cerebrospinal fluid